In Phase C, individuals will get ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment until illness progression or maybe the contributors are not able to tolerate the study drugs. Over-all, our existing work highlights the potential utilization of ARV-825 in combination https://jamesl776alv9.hyperionwiki.com/user